Drug Trial Radar · NCT07652814
Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Oct 13, 2022
Primary completion
Mar 9, 2028
Study completion Mar 9, 2028
Sponsor
- Lead sponsor
- Iris PlugAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to study the efficacy and safety of treatment with avalglucosidase alfa in patients with late onset Pompe disease that previously deteriorated on alglucosidase alfa. The main question it aims to answer is: * Is switching to avalglucosidase alfa in late-onset Pompe patients deteriorating on alglucosidase alfa safe? * Is switching to avalglucosidase alfa in late-onset Pompe patients deteriorating on alglucosidase alfa potentially more effective? Participants will switch to biweekly avalglucosidase alfa infusions (instead of alglucosidase alfa infusions) and perform assessment for: * Efficacy: muscle strength and function, pulmonary function, patient-reported outcomes. * Safety: Adverse events assessment, physical examination, clinical laboratory evaluations, vital signs, ECGs and immunogenicity assessments. * Pharmacokinetic assessments during 2 avalglucosidase alfa infusions.
Conditions
- Glycogen Storage Disease Type II Late Onset
- Pompe Disease (Late-onset)
- Pompe Disease Late-Onset
- Pompe's Disease Juvenile Onset
- Pompe Disease
Interventions
Avalglucosidase AlfaDrug
Enzyme replacement therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence/occurrence of adverse eventsTime frame: From enrollment to the end of study duration at 5 years
- The occurence of antibodies against avalglucosidase alfaTime frame: From enrollment to the end of study duration at 5 years
- Clinical laboratory evaluations aimed at liver and muscle function.Time frame: From enrollment to the end of study duration at 5 years
- Changes in muscle strength using manual muscle testing (MMT)Time frame: From enrollment to the end of study duration at 5 years
- Changes in muscle strength using hand-held dynamometry (HHD)Time frame: From enrollment to the end of study duration at 5 years
- Changes in muscle function using Quick Motor Function Test (QMFT)Time frame: From enrollment to the end of study duration at 5 years
- Changes in muscle function using the 6-Minute Walk Test (6-MWT)Time frame: From enrollment to the end of study duration at 5 years
- Changes in muscle function using timed testsTime frame: From enrollment to the end of study duration at 5 years
- Changes in pulmonary function using forced vital capacity (FVC)Time frame: From enrollment to the end of study duration at 5 years
- Changes in pulmonary function using Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP)Time frame: From enrollment to the end of study duration at 5 years
- Changes in patient reported outcome (PRO) measures using the Rasch-built Pompe-specific Activity scale (R-PAct)Time frame: From enrollment to the end of study duration at 5 years
- Changes in patient reported outcome (PRO) measures using the 36-Item Short Form Health Survey (SF-36)Time frame: From enrollment to the end of study duration at 5 years
- Changes in patient reported outcome (PRO) measures using the TNO-AZL Child Quality of Life Questionnaire)Time frame: From enrollment to the end of study duration at 5 years
- Changes in patient reported outcome (PRO) measures using the modified Borg scaleTime frame: From enrollment to the end of study duration at 5 years
- Pharmacokinetics of avalglucocidase alfaTime frame: From enrollment up to 1 year of study duration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Erasmus MC
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.